ArticleJournal of pediatric gastroenterology and nutrition2026
Using machine learning to predict clinical remission with exclusive enteral nutrition in pediatric Crohn disease.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial Intelligence in Clinical Nutrition: Current Uses, Challenges, and Opportunities.Nutrients · 2026Review
- Using machine learning to predict clinical remission with exclusive enteral nutrition in pediatric Crohn disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Artificial Intelligence in the Nutritional Management of Inflammatory Bowel Disease: A Scoping Review.Journal of multidisciplinary healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesExclusive enteral nutrition (EEN) is a first-line treatment for induction of remission in luminal pediatric Crohn disease (pCD). However, as the efficacy of EEN varies from patient to patient, there is a need to distinguish between responders and nonresponding patients. This study had two aims. First, to develop a model to predict EEN-induced clinical remission (weighted pediatric CD activity index [wPCDA] ≤ 12.5) using baseline clinical information. Second, to develop a model to predict corticosteroid-free sustained clinical remission post-EEN induction (wPCDA ≤ 12.5, for ≥36 weeks after EEN).
methodsWe applied machine learning to clinical and laboratory data from a prospectively followed cohort of pCD patients who received EEN as their first treatment for CD (n = 308). This learning algorithm used feature selection and k-fold (internal) cross-validation to systematically find the model with the best combination of features and hyperparameter settings. To estimate the quality of the learned model, we used k-fold (external) cross-validation.
resultsClinical, laboratory, and treatment data were compiled into two different datasets: EEN clinical remission at the end of EEN treatment (mean of 60 days; n = 114) and corticosteroid-free sustained clinical remission post-EEN induction (n = 206). Our resulting models were effective, with external area under the curves of 0.65
conclusionOur models, based on accessible clinical features, were able to effectively predict EEN success above chance. This supports the plausibility of building clinical tools to assist precision therapy for pCD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.